AbbVie (NYSE:ABBV) Releases Quarterly Earnings Results, Misses Expectations By $0.36 EPS

AbbVie (NYSE:ABBV) announced its quarterly earnings data on Wednesday. The company reported $2.65 EPS for the quarter, missing the consensus estimate of $3.01 by ($0.36), FiscalAI reports. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.46 EPS.

Here are the key takeaways from AbbVie’s conference call:

• AbbVie beat Q1 expectations with adjusted EPS of $2.65 and $15 billion in revenues, and raised full?year adjusted EPS guidance by $0.12 to $14.08–$14.28, citing stronger-than-expected demand across the portfolio.
• Immunology momentum remains a key driver—SKYRIZI sales were $4.5B (up ~29% operationally) and management now models ~$21.6B for 2026, while RINVOQ reached $2.1B (up ~20%) with a $10.2B full?year assumption, both outperforming expectations.
• Pipeline progress in gastroenterology was highlighted—subcutaneous induction SKYRIZI for Crohn’s was submitted in the U.S. with an approval decision expected later this year, and a combo of SKYRIZI + ABBV?382 showed ~42% endoscopic remission at week 24 in a highly refractory cohort, suggesting potentially transformational efficacy.
• Early-stage R&D catalysts include encouraging obesity data for the long?acting amylin analog ABBV?295 (~10% weight loss in 12 weeks, good tolerability) and an accelerated oncology plan with etentamig now expected to be submitted by year?end, both cited as near?term growth opportunities.
• The FDA issued a complete response letter for TrenibotE due to manufacturing questions (no safety/efficacy issues), delaying a U.S. approval path while international launches are still expected later this year.

AbbVie Trading Up 3.3%

NYSE ABBV traded up $6.51 during mid-day trading on Wednesday, hitting $204.20. The company’s stock had a trading volume of 10,385,505 shares, compared to its average volume of 7,173,595. The company’s 50 day simple moving average is $215.29 and its 200 day simple moving average is $221.79. AbbVie has a twelve month low of $176.57 and a twelve month high of $244.81. The firm has a market capitalization of $361.06 billion, a price-to-earnings ratio of 86.53, a PEG ratio of 0.71 and a beta of 0.38.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.4%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ABBV. UBS Group reduced their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Finally, Guggenheim lifted their price target on shares of AbbVie from $242.00 to $249.00 and gave the company a “buy” rating in a research report on Friday, April 10th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $253.19.

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.06% of the stock is owned by insiders.

Hedge Funds Weigh In On AbbVie

A number of hedge funds have recently bought and sold shares of the company. State Street Corp boosted its holdings in AbbVie by 1.4% during the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after acquiring an additional 1,119,274 shares during the last quarter. Bank of America Corp DE boosted its holdings in AbbVie by 1.4% during the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after acquiring an additional 356,394 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of AbbVie by 41.7% during the 4th quarter. Wellington Management Group LLP now owns 14,926,683 shares of the company’s stock worth $3,410,598,000 after purchasing an additional 4,389,782 shares during the period. Amundi raised its stake in shares of AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock worth $2,418,909,000 after purchasing an additional 1,414,621 shares during the period. Finally, Raymond James Financial Inc. raised its stake in shares of AbbVie by 2.4% during the 3rd quarter. Raymond James Financial Inc. now owns 9,557,701 shares of the company’s stock worth $2,212,110,000 after purchasing an additional 220,221 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 revenue beat and guidance raise — AbbVie reported Q1 net revenue of $15.00B (above consensus) and raised 2026 adjusted EPS guidance to $14.08–$14.28 from $13.96–$14.16, supporting the rally. AbbVie Reports First-Quarter 2026 Financial Results
• Positive Sentiment: Blockbuster immunology drivers — Skyrizi and Rinvoq generated the bulk of growth (Skyrizi roughly $4.48B; Rinvoq ~$2.12B), helping offset Humira declines and underpinning top-line momentum. AbbVie Thanks ‘Excellent Start To 2026’ To Immunology And Neuroscience Strength
• Positive Sentiment: Regulatory and trial progress for Rinvoq — AbbVie submitted an FDA application for Rinvoq in severe alopecia areata and reported positive head?to?head data versus Humira in RA subpopulations, which expand commercial upside. AbbVie Submits Application to FDA for Upadacitinib (RINVOQ)
• Positive Sentiment: Early-stage strategic deals — AbbVie secured development/options exposure to KRAS programs (option to buy Kestrel up to $1.45B) and milestone-driven collaborations, signaling pipeline diversification beyond core franchises. AbbVie sinks talons into KRAS with right to buy Kestrel
• Neutral Sentiment: Technical / analyst notes — Some market commentary frames the post-earnings pullback earlier in 2026 as a buy opportunity for income/long-term investors, which may sustain interest from dividend-focused holders. AbbVie Fires Healthy Trend-Following Signal
• Neutral Sentiment: Dividend and infrastructure — AbbVie remains highlighted for dividend strength and is investing in R&D/site expansion (Research Triangle plans), factors that support longer-term yield and growth narratives. AbbVie Maintains Dividend Strength
• Negative Sentiment: Humira and legacy declines persist — Humira revenue continues to fall (Q1 ~ $688M), and some oncology products declined, keeping pressure on margins and the need for continued newer?product uptake. AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
• Negative Sentiment: Mixed accounting/earnings items — GAAP EPS and some metric noise (acquired IPR&D and milestone charges, GAAP EPS down materially year?over?year) and differing EPS comparisons in the press created volatility and short?term sentiment headwinds. AbbVie Earnings Report / Conference Call

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.